Evaluating Erythropoietin as an Indicator for Possible Kidney Injury After Cardiac Surgery (EPO)
Recruitment status was: Recruiting
Acute Kidney Injury
|Study Design:||Observational Model: Case-Only
Time Perspective: Cross-Sectional
|Official Title:||EPO: A Renal Biomarker After Cardiac Surgery|
|Study Start Date:||November 2010|
|Estimated Primary Completion Date:||December 2011 (Final data collection date for primary outcome measure)|
Acute kidney injury (AKI) is a serious complication after cardiac surgery and cardio-pulmonary bypass. AKI is associated with high mortality.
Erythropoietin, a hormone produced by the kidneys, will be evaluated as a potential biomarker of kidney injury. Neutrophil gelatinase-associated lipocalin (NGAL)has been studied as a biomarker of kidney injury. Early kidney injury detection has been long sought and NGAL has been shown to be a promising biomarker. A troponinlike biomarker of AKI that is easily measured and capable of both early detection and risk stratification would represent an advancement in our ability to differentiate acute kidney injury from failure.
Investigating EPO as a biomarker may prove to have increased predictive value in the clinical care of cardiac surgery patients.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01393418
|United States, Michigan|
|University of Michigan Hospital|
|Ann Arbor, Michigan, United States, 48109|
|Principal Investigator:||Yasser El Kouatli, MD||Department of Anesthesiology, University of Michigan|